A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

clinical trial

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT00942578

P6099clinical trial phasephase II clinical trialQ42824440
P17countryUnited States of AmericaQ30
P582end time2017-07-31
P921main subjectmetastatic prostate carcinomaQ55779807
P4135maximum age100
P2899minimum age18
P1132number of participants63
P4844research interventionbevacizumabQ413299
prednisoneQ424972
(RS)-lenalidomideQ425681
P6153research siteNational Institutes of HealthQ390551
P580start time2009-07-16
P8363study typeinterventional studyQ78089383
P1476titleA Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Search more.